혈액암 (AML/ALL)

558개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved558 programs
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 3

nivolumab (Opdivo, NAI + Nivolumab + Ipilimumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ImmunityBio
Trials 1Status Discontinued
AntibodyLimited DatastaleImmunityBio, Inc.Phase 3

pembrolizumab (Keytruda, NAI + Pembrolizumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ImmunityBio
Trials 1Status Discontinued
CGTLimited DatastaleCelyad Oncology SAPhase 1

NKR-2 CAR-T Cells (NKR-2 CAR-T Cells)

AML, Adult; Myelodysplastic Syndromes · AML, Adult

#AMLAdult#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleNkarta, Inc.Phase 1

NKX101 - CAR NK cell therapy (NKX101 - CAR NK cell therapy)

Relapsed/Refractory AML; AML, Adult · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T (Nanobody-Based CD19/CD22 Tandem Dual CAR-T)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleAbGenomics B.V Taiwan BranchPhase 2

Neihulizumab Treatment (Neihulizumab Treatment)

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation · FRα

#FR#Antibody#Phase2#monoclonal-antibody#Steroid-refractoryaGvHDSubsequen+1
Trials 1Status Discontinued
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

New donor-derived CD7 CAR T-cell (New donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Newly matched donor-derived CD5 CAR T-cells (Newly matched donor-derived CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleWashington University School of…Phase 2

Nogapendekin alfa inbakicept (Nogapendekin alfa inbakicept)

Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent · Non-small Cell Lung Cancer Stage IV

#Non-smallCellLungCancerStageIV#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerRecurrent+1
Trials 1Status Recruiting
CGTLimited DatastaleTimmune Biotech Inc.Phase 1

Novel CAR-T (Novel CAR-T)

B-cell Non Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleGenta IncorporatedPhase 2

Oblimersen-rituximab-fludarabine (Oblimersen-rituximab-fludarabine)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#monoclonal-antibody#Genta
Trials 1Status Active
AntibodyLimited DatastaleAssistance Publique Hopitaux De…Phase 2

MEDI9447 (Oleclumab, Oleclumab (MEDI9447))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Assistance
Trials 1Status Recruiting
CGTLimited DatastalePoseida Therapeutics, Inc.Phase 1

P-BCMA-ALLO1 CAR-T cells (P-BCMA-ALLO1 CAR-T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastalePoseida Therapeutics, Inc.Phase 1

P-MUC1C-ALLO1 CAR-T cells (P-MUC1C-ALLO1 CAR-T cells)

Breast Cancer; Ovarian Cancer · Breast Cancer

#BreastCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

PACE CART19 (PACE CART19)

Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued

23 / 28 pages

← PreviousNext →